Drugs.com Clinical Trial ResultsOriginal article
BlueRock Therapeutics’ Investigational Cell Therapy Lemiretprocel (OpCT-001) for Primary Photoreceptor Diseases Granted Orphan Drug Designations by FDA and EMA
RegulatoryLemiretprocelPositive
AI Analysis
Summary
BlueRock Therapeutics' investigational cell therapy Lemiretprocel (OpCT-001) for primary photoreceptor diseases has received Orphan Drug Designation from both the FDA and EMA, supporting development of this rare disease treatment.
Outcome Details
Orphan Drug Designation granted by FDA and EMA
Importance:6/10
Sentiment:
0.65
orphan_drug_designationcell_therapyophthalmologyrare_diseaseFDAEMA
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 30, 2026 10:09 PM